8 Penggunaan Insulin Pada Kasus Kedaruratan Medik

7/26/2019 8 Penggunaan Insulin Pada Kasus Kedaruratan Medik

http://slidepdf.com/reader/full/8-penggunaan-insulin-pada-kasus-kedaruratan-medik 1/46

PB.PERKENI

Treatment Insulin

&Hyperglicemia

Crisis



DISCUSSION

HYPOGLYCEMIA

HYPERGLYCEMIC HYPEROSMOLAR STATE

DIABETIC KETOACIDOSIS



In 1552 BCDiabetes 1st Descibe! In "itin#

Ea$iest %n&'n ec&! &( !iabetes)enti&ne! &n *! D+nast+ E,+-tian

-a-+.s b+ -/+sician Hes+0Ra)enti&ns -&$+.ia as a s+)-t&)

253 BC4 A-&$$&ni.s &( Me)-/is c&ine!

t/e na)e !iabetes6 )eanin# t& #&t/&.#/ & si-/&n He .n!est&&! t/att/e !isease !aine! )&e 7.i! t/an a-es&n c&.$! c&ns.)e

http://images.google.com/imgres?imgurl=http://www.shopategypt.com/store/images/papyrus-painting-002b.jpg&imgrefurl=http://www.shopategypt.com/store/product_info.php?cPath=94_116&products_id=276&h=727&w=727&sz=51&hl=en&start=2&um=1&tbnid=YxhetIHHQsr_oM:&tbnh=141&tbnw=141&prev=/images?q=egyptian+papyrus&um=1&hl=en&sa=N

http://www.malaspina.edu/~mcneil/jpg/apollonius.jpg

http://images.google.com/imgres?imgurl=http://www.shopategypt.com/store/images/papyrus-painting-002b.jpg&imgrefurl=http://www.shopategypt.com/store/product_info.php?cPath=94_116&products_id=276&h=727&w=727&sz=51&hl=en&start=2&um=1&tbnid=YxhetIHHQsr_oM:&tbnh=141&tbnw=141&prev=/images?q=egyptian+papyrus&um=1&hl=en&sa=N



Ea$+ Diabetes

Disc&8eiesIn t/e 19:;4 Pa.$ Lan#e/ans4 a

Ge)an )e!ica$ st.!ent ann&.nce!

in a !issetati&n4 t/at t/e -anceas

c&ntains t'& s+ste)s &( ce$$s

199; Os%a Min%&'s%i an! <&se-/

8&n Mein# in =ance4 e)&8e! t/e-anceas (&) a !&# t& !ete)ine t/ee>ect &( an absent -anceas &n

!i#esti&n



Fred Banting (1891-1941) Charles H. Best (1899-1978) John J.R. McLeod (187-19!")Fred Banting (1891-1941) Charles H. Best (1899-1978) John J.R. McLeod (187-19!")

Ja#es B. Colli$Ja#es B. Colli$

(189%-19")(189%-19")Mar&orie ('-')Mar&orie ('-')

he isco*er+ o, nslin

(oronto 19%1)



Le&na! T/&)-s&n T/e ?st -atient t& ecei8e [email protected]&ns &(

-anceatic etact &n <an.a+ 114 1;22 He'as 1 T/e +&.n# T&&nt& esi!ent /a!

been !iabetic since 1;1; He 'ei#/e! &n$+:5 -&.n!s an! 'as ab&.t t& s$i- int& ac&)a an! !ie At ?st /e ecei8e! D4 =Bantin#s an! D C/a$es Bests etact

T'& 'ee%s $ate /e .se! t/e -.i?e!etact &( D <B C&$$i- an! T/&)-s&ns

s+)-t&)s be#an t& !isa--ea /is b$&&!s.#a et.ne! t& n&)a$ an! /e 'asbi#/te an! st&n#e T/&)-s&n $i8e!an&t/e 1* +eas 'it/ t/e ins.$in He !ie!at t/e a#e &( 2F !.e t& -ne.)&nia4 a

c&)-$icati&n &( /is !iabetes :



HYPOGLYCEMIA

H+-&#$+ce)ia is a b$&&! #$.c&se 8a$.e &($ess t/an 53 )#!$

C$inica$$+4 it is !e?ne! b+ "/i--$e tia! $&'

-$as)a #$.c&se $e8e$4 s+)-t&)s c&nsistent'it/ /+-&#$+ce)ia4 an! es&$.ti&n &(s+)-t&)s 'it/ c&ecti&n &( -$as)a#$.c&se



E-i!e)i&$&#+

*3 &( t+-e 1 & t+-e 2 !iabetic -atients &nins.$in t/ea-+

13 &( t+-e 2 !iabetic -atients

M&ta$it+ ate *0 es-ecia$$+ e$!e$+ ta%in#$&n# actin# &a$ /+-&#$+ce)ic a#ents



S+)-t&)s

A!ene#ic s+)-t&)s catec/&$a)ine )e!iate!J !ia-/&esis4 -a$-itati&ns4 -a$$&4 tac/+ca!ia a--e/ensi&n4 aniet+4 sensati&n &( /.n#e

/ea!ac/e4 'ea%ness4 est$essness

Ne.&#$+c&-enic s+)-t&)se!.ce! inte$$ect.a$ ca-acit+4 iitabi$it+4c&n(.si&n4 abn&)a$ be/a8i&4c&n8.$si&n4 c&)a



G$.c&e#.$at&+ (act&s

Blood-glucose-loweringfactor

Blood-glucose-raisingfactors

Insulin

Glucose-counterregulatoryfactors

Glucagon

Epinephrine

Growth hormoneCortisol

in minutes

In hours



P/+si&$&#ic es-&nse in /+-&#$+ce)ia

B$&&! #$.c&se 5:09 )#!$

a!ena$in seceti&n

!ia-/&esis4 te)&

e!.ce! (.ncti&n &( centa$ ne8&.s s+ste)

B$&&! #$.c&se 90*: )#!$

e!.ce! c&nsci&.sness

B$&&! #$.c&se *:019 )#!$

c&)a4 c&n8.$si&n B$&&! #$.c&se 19 )#!$

-e)anent bain !a)a#e





S+n!&)es &( c&)-&)ise! #$.c&sec&.ntee#.$ati&n in t+-e 1 !iabetes )e$$it.s

De(ecti8e #$.c&se c&.ntee#.$ati&n

I)-aie! a'aeness &( /+-&#$+ce)ia

E$e8ate! #$+ce)ic t/es/&$! !.in# intensi8e t/ea-+

E$e8ate! #$+ce)ic t/es/&$! (&$$&'in# ecent/+-&#$+ce)ia

E$e8ate! #$+ce)ic t/es/&$! !.in# ß-adrenergicblockade

The syndromes may occur in advanced type 2 diabetes mellitus(insulin-deficient

!utonomic failure



Sc/e)atic !ia#a) &( t/e c&nce-t &( /+-&#$+ce)ia0ass&ciate! a.t&n&)ic (ai$.e in T1DM

Ins.$in !e?cienc+ IDDM

N& #$.ca#&n es-&nses t& !ecease! #$.c&se $e8e$s

E-ine-/inees-&nses

I)-e(ect ins.$ines-&nses

E-is&!es &( /+-&#$+ce)ia

H+-&#$+ce)ia0ass&ciate! a.t&n&)ic (ai$.e

s+)-t&)atic es-&nses a'aenessJ a.t&n&)ic inc$.!in# e-ine-/ineJ es-&nses





Ris% (act&s

Ti#/t #$+ce)ic c&nt&$

A#e

D.ati&n &( !iabetes

Hist&+ &( /+-&#$+ce)ia S$ee-in#

A$c&/&$is)

=astin#

Incease! ins.$in sensiti8it+ ?tness4 b&!+ 'ei#/t

C$eaance)etab&$is) &( !.#s ena$ & /e-aticins.cienc+



Mec/anis)s b+ '/ic/ !.#s incease t/e/+-&#$+ce)ic e>ect &( s.$(&ni$.eas

Incease in /a$(0$i(e !.e t& in/ibiti&n &( )etab&$is)& eceti&n ate et/an&$4 -/en+$b.ta&ne4c&.)ain antic&a#.$ants4 c/$&a)-/enic&$4!&+c+c$ine4 s.$(&na)i!es4 a$$&-.in&$

C&)-etiti&n (& a$b.)in0bin!in# sites-/en+$b.ta&ne4 sa$ic+$ates4 s.$(&na)i!es

In/ibiti&n &( #$.c&ne&#enesis4 incease in #$.c&se&i!ati&n4 & sti).$ati&n &( ins.$in seceti&net/an&$4 ß-adrenergic drugs, monoamine oxidaseinhibitors, tranylcypromine, t



Mana#e)ent &( /+-&#$+ce)ia

Mi$! /+-&#$+ce)ia '/en se$( teat)ent'it/ &a$ cab&/+!ate s.ces

Se8e /+-&#$+ce)ia '/en etena$ /e$- is

e,.ie! t& e>ect ec&8e+



Mana#e)ent &( /+-&#$+ce)ia Pe8enti&n

1 Ea$+ (a)i$iaiati&n 'it/ t/e s+)-t&)s &(/+-&#$+ce)ia

2 D& e8ie'in# at inte8a$s

* E-$ain t/e e$ati&ns/i- bet'een ins.$ina!)inistati&n4 ti)in# &( )ea$s4 an! eecise

E-$ain )et/&!s &( se$(0teatin# /+-&#$+ce)ia

5 C/&&se a--&-iate ins.$in e#i)ens4 !&sesc/e!.$es 'it/ a--&-iate t/ea-e.tic #&a$s



Mana#e)ent &( /+-&#$+ce)ia Teat)ent

Mi$! /+-&#$+ce)ia &a$ #$.c&se 15023 #4 'ait 13015)in t/en c/ec% b$&&! #$.c&se I( #$.c&se $e8e$ !&esn&t incease 19 )#!$4 #i8e &a$ #$.c&se a#ain

Se8e /+-&#$+ce)ia s&$.ti&n 53 )$ &( !et&se 53

#i8en inta8en&.s$+4 c/ec% b$&&! #$.c&se in 23 )inI( it is sti$$ /+-&#$+ce)ia a!)inistate &nce a#ain

G$.ca#&n 13 )# sci)i8 a!8ese e>ects inc$.!ena.sea4 8&)itin#4 an! /ea!ac/e C&ntain!icate! t&s.$(&n+$.eas0in!.ce! /+-&#$+ce)ia Ine>ecti8e in

-atient '/& is an&ectic4 & 'it/ -&tacte!/+-&#$+ce)ia



DIABETIC KETOACIDOSIS

AND

HYPERGLYCEMIC HYPEROSMOLAR STATE

Pathogenesis of DKA



Pathogenesis of DKA

and HHS

"I!BETE# C!$E% &')*E 2+% ,)*BE$ 2% "ECE*BE$ 2.





DKADIABETIC KETOACIDOSISJ

Occ.s '/en ).sc$e ce$$s bec&)e s& sta8e! (&ene#+ t/at b&!+ ta%es e)e#enc+ )eas.es Qbea%s !&'n (at t&ic aci!s as %et&nes

M&st c&))&n t+-e 1 DM ins.cient ins.$in t&

[email protected] aise &( b$&&! s.#a Ca.se b+ ete)e stess & i$$ness In(ecti&n b&!+ -&!.ce a!ena$in '&%s

a#ainst ins.$in

=&#et t& ta%e ins.$in



DKA diagnostic criteria:

serum glucose 250 mg/dl,arterial pH 7.3,serum bicarbonate 18 mEq/l,

moderate ketonuria or ketonemia.

HHS diagnostic criteria:

serum glucose 00 mg/dl,arterial pH 7.3, serum

bicarbonate 15 mEq/l,minimal ketonuria and ketonemia

"I!BETE# C!$E% &')*E 2+% ,)*BE$ 2% "ECE*BE$ 2../



Si#ns Q s+)-t&)s &( DKA

Dee-4 a-i! beat/in# S'eet4 (.it+ s)e$$ &n beat/ L&ss &( a--etite Na.sea &)itin# =e8e

St&)ac/ -ain "ei#/t $&ss

• Fatigue• Weakness• Confusion• Drowsiness



C$inica$ -esentati&n

L&st )&e t/an 5 b&!+ 'ei#/t

M&e t/an *5 beat/s a )in.te

Cant c&nt&$ b$&&! s.#a Bec&)e c&n(.se!

Na.sea an! 8&)itin#



"/at s/&.$! +&. !&

C/ec% %et&nes i( (ee$in# es-ecia$$+stesse! & b$&&! s.#a -esistent$+ ab&8e23)#!L

Hi#/ %et&nes in b$&&! %et&nes ecete!in .ine

Hi#/ %et&nes in .ine s/&.$! be teate! Qn /&s-ita$ie!

DKA can $ea! int& c&)a an! -&ssib$+!eat/



Teat)ent

C&ectin# $&st 7.i!s t/&.#/ i8 $ine

G$.c&se in(.si&n 'it/ ins.$in )a+st&- %et&nes -&!.cti&n

Decease b$&&! s.#a $e8e$ #a!.a$$+4!eceasin# #$.c&se a-i!$+ )a+

-&!.ce bain s'e$$in#





HHS HYPERGLYCEMIC HYPEROSMOLAR STATEJ

A /i#/ $e8e$ &( b$&&! #$.c&se )a+ inte(ee b$&&!cic.$ati&n $e8e$ >:33 )#!$J

G$.c&se .-ta%e b+ t/e ce$$s !eceases4 t/e #$.c&se-asse! (&) b$&&! t& .ine !a's te)en!&.s

a)&.nts &( 7.i! (&) b&!+ an! -&!.ces !e/+!ati&n

C&))&n in t+-e 2 DM4 es-ecia$$+ '/& !&es n&t)&nit& b$&&! s.#a4 an! '/& !&es n&t %n&' /a8eDM

Ti##e (act&s /i#/0!&se ste&i!4 !i.etics4 in(ecti&n4i$$ness4 stess & !in%in# ecessi8e a$c&/&$



HHS si#ns Q s+)-t&)s

Ecessi8e t/ist Incease! .inati&n "ea%ness Le# ca)-s C&n(.si&n Ra-i! -.$se

C&n8.$si&ns C&)a



"/at s/&.$! +&. !&

C/ec% b$&&! #$.c&se $e8e$ > :33)#!LJ

E)e#enc+ teat)ent can c&ect t/e-&b$e) 'it/in /&.s

Gi8e inta8en&.s 7.i!s t& est&e 'ate t&t/e tiss.e

S/&t actin# ins.$in t& /e$- ce$$s can .-ta%e#$.c&se

"it/&.t -&)-t teat)ent can be (ata$







Conclsion /

0er+ lo dose inslin a$$lication and slo #otionre-e2ili3ration $ls #onitored s3stittion o,

electrol+tes are the 3asic strategies in the treat#ent

o, se*ere 5





GROUP I (Subcutant-1hour)• nitial dose 6C / ! nits:g

3od+ t ,olloed 3+• 6C as$art inslin at 1

nits:g e*er+ hor • ;hen 3lood glcose < %"

#gdl change 0 ,lids to"= 4"= saline and redce6C as$art inslin to ."nits:ghor to :ee$glcose at % #gdl ntilresoltion o, 5

La3orator+ chec: :a. Admission : Cell blood count with differential complete metabolic profile, venous p, and serum !"

h#dro$#but#rate

b. During treatment : %asic metabolic profile &glucose, bicarbonate, sodium, potassium, chloride, urea, andcreatine', venous p, phosporus, and !"h#dro$#but#rate at ( h, ) h and ever# ) h until resolution of D*A

c. +lucose b# finger stick : Check glucose ever# h in patients receiving -C" h and ever# ( h in patient /insulin or receiving -C"( h

GROUP II (Subcutant-2hour)• nitial dose 6C / ! nits:g

3od+ t ,olloed 3+• 6C as$art inslin at % nits 1

hor later and e*er+ % hor • ;hen 3lood glcose < %"

#gdl change 0 ,lids to"= 4"= saline and redce6C as$art inslin to .1nits:g e*er+ % hor to :ee$glcose at % #gdl ntilresoltion o, 5

GROUP III (Intravena RI)• nitial 0 3ols / .1 nits:g

3od+ t ,olloed 3+• Continos inslin in,sion

at .1 nits:ghor• ;hen 3lood glcose < %"

#gdl change 0 ,lids to"= 4"= saline and redceinslin in,sion rate to ."nits:g hor to :ee$glcose at % #gdl ntilresoltion o, 5

RESEARCH DESIGN & E!HODS

0mpierre1 +2, Diabetes Care (33) 4 (5 : 657"656



>#$ierre? @A ia3etes Care %4 %7 / 187!-1878

S"#"$ar Re%on%e o' e"ca$ treat#ent"th SC A%art "n co#ar"%on "th I* RI

ote / 6C-1h / 63ctaneos as$art e*er+ 1 hor 6C- %h / 63ctaneos as$art e*er+ % hor



S"#"$ar +$uco%e ro'"$e %ubcutaneou%In%u$"n A%art "n co#ar"%on "th

"ntravenou% Re+u$ar In%u$"n

333

33

(33

)33

833

633

6 ( 8 (3) ()

ration o, treat#ent (hors)

@ l . c o s e ( #

g 9 d l )


6C o*oRa$id D e*er+ 1 hr

6C o*oRa$id D e*er+ % hr

0 Reglar nslin



8

,8

,)

,(

,36

(,3

6

(,)

(,(

%11%4 8 %%

B i c a r 3 o n a t e ( # #

o l 9 L )

ration o, treat#ent (hors)


S"#"$ar ,"carbonate ro'"$e "th%ubcutaneou% In%u$"n A%art "n co#ar"%on

"th "ntravenou% Re+u$ar In%u$"n

6C o*oRa$id D e*er+ 1 hr

6C o*oRa$id D e*er+ % hr

0 Reglar nslin



S"#"$ar #etabo$"c ro'"$e "th%ubcutaneou% In%u$"n A%art

"n co#ar"%on "thIntravenou% Re+u$ar In%u$"n




Diabetes Care Publish Ahead of Print, published online April 1, !""#



Re%u$t

ia3etes Care E3lish 5head o, Erint $3lished online 5$ril 14 %9

5nalog nslin Reglar nslin



.earn"n+ 'ro# U#"erre/ Protoco$#ubcutaneous insulin !spart every 2 hour

9aborator# check :

a. Admission : Cell blood count with differential complete metabolic profile, venous p, and serum !"h#dro$#but#rate

b. During treatment : %asic metabolic profile &glucose, bicarbonate, sodium, potassium, chloride, urea, andcreatine', venous p, phosporus, and !"h#dro$#but#rate at ( h, ) h and ever# ) h until resolution of D*A

c. +lucose b# finger stick : Check glucose ever# ( h in patinet receiving -C"( h


Subcutaneou% "n%u$"n A%art ever0 2 hour

• nitial dose 6C / ! nits:g 3od+ t ,olloed 3+• 6C as$art inslin at % nits 1 hor later and e*er+ % hor • ;hen 3lood glcose < %" #gdl change 0 ,lids to "= 4"= saline and

redce 6C as$art inslin to .1 nits:g e*er+ % hor to :ee$ glcose at %#gdl ntil resoltion o, 5



8 Penggunaan Insulin Pada Kasus Kedaruratan Medik

Text of 8 Penggunaan Insulin Pada Kasus Kedaruratan Medik

KEDARURATAN LINGKUNGAN

BUKU PANDUAN MAHASISWA KEDARURATAN MEDIK DENTAL …akademikpdgub.staff.ub.ac.id/files/2019/07/BPM-Blok-13-TA-2019-2020.pdf · fakultas kedokteran gigi – universitas brawijaya 1

NOMOR 9 TAHUN 2012 TENTANG RETRIBUSI PELAYANAN · PDF file2010 tentang Pedoman Pembentukan Peraturan Daerah ... (IGD) adalah tempat pelayanan medik yang menangani kasus-kasus kedaruratan

KEDARURATAN PSIKIATRI

KEDARURATAN MEDIK PADA LANJUT USIAkaryatulisilmiah.com/wp-content/uploads/2016/03/BAB-5... · Web viewHenti jantung merupakan suatu keadaan yang patologis di mana jantung berhenti

KEDARURATAN NEUROLOGI

BRIDGING THE GAP BIAYA REGISTRASI BETWEEN … ke-5 FK Unjani.pdf · Morbiditas dan mortalitas dalam kasus kedaruratan medik sangat ditentukan oleh kecepatan dan ketepatan dalam melakukan

Kedaruratan Obstetri

Laporan Tutorial Sken 2 Kedaruratan Medik

Laporan Tutorial Skenario blok kedaruratan medik

Trauma Extremitas - Kedaruratan Medik (2)

PELAYANAN KEDARURATAN MEDIK SEBAGAI MATA RANTAI KEHIDUPAN …

BAB I&II Kedaruratan Medik(Ok)

KEDARURATAN MEDIK PADA LANJUT USIA · Web viewPada lanjut usia berbagai fungsi organ tubuh mengalami penurunan, demikian halnya dengan jantung, terjadi penurunan heart rate, sklerosis

05 KEDARURATAN MEDIK

KEDARURATAN PSIKIATR1

Kedaruratan Psikiatrik

KEDARURATAN OBSTETRIK

Kedaruratan Persalinan

PEMERINTAH KABUPATEN KOTAWARINGIN BARAT PERATURAN … · 2019. 9. 15. · 13. Pelayanan Rawat Darurat adalah pelayanan kedaruratan medik yang harus diberikan secepatnya untuk mencegah/menanggulangi

Kedaruratan URO

Kedaruratan Hidung

PERATURAN DAERAH KAB UPATEN LAMPUNG UTARA NOMOR … · pemeriksaan laboratorium dan radio diagnostik. 17. Pelayanan Gawat Darurat adalah pelayanan kedaruratan medik yang harus diberikan

KEDARURATAN FRAKTUR

DAFTAR PUSTAKA - UNISSULArepository.unissula.ac.id/6011/7/DAFTAR PUSTAKA_1.pdfMaster Plan Kedaruratan Medik. Tangerang Selatan : Binapura Aksara Publisher. Lewis, dkk. (2011). Medical

BUKU PANDUAN MAHASISWA KEDARURATAN MEDIK DENTAL …akademikpdgub.staff.ub.ac.id/files/2017/08/BPM-15K.pdf · I.4 Topik 1 : Manajemen Kesehatan Skenario 1 : Pelayanan Primer Prior

PENANGGULANGAN MEDIK KEDARURATAN NUKLIR Medik... · Petugas Triage melakukan pembagian kemana pasien untuk tindakan selanjutnya 6. PPR melakukan pengukuran dan memantau tingkat

gowakab.go.id · untuk kasus kedaruratan medik: 24 jam) yang diberikan Oleh petuges kesehatan kepada segrorang dan/atau sekelompck_crang sebagai ... seorang pasien, baik yang bersifat

Kedaruratan Pediatrik

Kedaruratan Medik Stroke Akut

Documents

8 Penggunaan Insulin Pada Kasus Kedaruratan Medik

Text of 8 Penggunaan Insulin Pada Kasus Kedaruratan Medik